-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ONRFeJ1IwEPNKxOKWBXCXlsYGfSRE0uy7yg/sWSwSptEGFHGdrGeeJhD4kC1ARwz 6iw4wlzrya8VdarZ+JHR9w== 0001193125-07-163195.txt : 20070726 0001193125-07-163195.hdr.sgml : 20070726 20070726172834 ACCESSION NUMBER: 0001193125-07-163195 CONFORMED SUBMISSION TYPE: S-8 POS PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070726 DATE AS OF CHANGE: 20070726 EFFECTIVENESS DATE: 20070726 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-8 POS SEC ACT: 1933 Act SEC FILE NUMBER: 033-58187 FILM NUMBER: 071004147 BUSINESS ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 S-8 POS 1 ds8pos.htm POST EFFECTIVE AMENDMENT #1 Post effective amendment #1

As filed with the Securities and Exchange Commission on July 26, 2007.

Registration No. 033-58187


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


POST-EFFECTIVE AMENDMENT NO. 1

To

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 


BRISTOL-MYERS SQUIBB COMPANY

(Exact name of registrant as specified in its charter)

 


Delaware

(State or other jurisdiction of incorporation or organization)

22-0790350

(I.R.S. Employer Identification No.)

 


345 Park Avenue, New York, N.Y. 10154

(Address, including zip code, of Principal Executive Offices)

Telephone: (212) 546-4000

 


BRISTOL-MYERS SQUIBB COMPANY TEAMSHARE STOCK OPTION PLAN,

As Amended and Restated Effective September 10, 2002

(Full title of the plans)

 


Sandra Leung

Senior Vice President and General Counsel

Bristol-Myers Squibb Company

345 Park Avenue, New York, N.Y. 10154

(212) 546-4000

(Name, address and telephone number, including area code, of agent for service)

 



EXPLANATORY STATEMENT

On March 23, 1995, a total of 60,000,000 shares of Common Stock, par value $.10 per share, of Bristol-Myers Squibb Company (the “Registrant”) were registered on Form S-8 (Registration No. 033-58187) for issuance under Registrant’s Teamshare Stock Option Plan (the “Teamshare Plan”). On May 1, 2007, the Registrant’s stockholders approved the Bristol-Myers Squibb Company 2007 Stock Award and Incentive Plan (the “2007 Plan”). No additional awards will be made under the Teamshare Plan. Pursuant to Instruction E to Form S-8 and interpretations of staff of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”), 11,900,000 of the unissued shares previously registered with respect to the Teamshare Plan are carried forward and deemed covered by the registration statement on Form S-8 relating to the 2007 Plan that was filed on the date hereof. An aggregate registration fee of $330,070 was paid in connection with the filing of Registration Statement No. 033-58187, of which $65,463.88 related to the 11,900,000 shares being carried forward.

PART II

 

Item 3. INCORPORATION OF DOCUMENTS BY REFERENCE.

The contents of registration statement on Form S-8 (Registration No. 033-58187) are hereby incorporated by reference.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in City of New York, and the State of New York, on July 13, 2007.

 

BRISTOL-MYERS SQUIBB COMPANY
By:  

/s/ James M. Cornelius

  James M. Cornelius
  Chief Executive Officer


Each person whose signature appears below hereby severally constitutes and appoints Andrew R.J. Bonfield, Sandra Leung and Sonia Vora, and each of them acting singly, as his or her true and lawful attorney-in-fact and agent, with full and several power of substitution and resubstitution, to sign for him or her and in his or her name, place and stead, in any and all capacities indicated below, the registration statement on Form S-8 filed herewith and any and all pre-effective and post-effective amendments and supplements to said registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his or her substitute, may lawfully do or cause to be done by virtue thereof.

 

Signature

  

Title

   

/s/ James M. Cornelius

  

Chief Executive Officer and Director

(Principal Executive Officer)

 
James M. Cornelius     

/s/ Andrew R.J. Bonfield

  

Executive Vice President and Chief

Financial Officer

 
Andrew R.J. Bonfield     

/s/ Joseph C. Caldarella

  

Vice President and Controller

(Principal Accounting Officer)

 
Joseph C. Caldarella     

/s/ Lewis B. Campbell

   Director  
Lewis B. Campbell     

/s/ Louis J. Freeh

   Director  
Louis J. Freeh     

/s/ Laurie H. Glimcher, M.D.

   Director  
Laurie H. Glimcher, M.D.     

/s/ Michael Grobstein

   Director  
Michael Grobstein     

/s/ Leif Johansson

   Director  
Leif Johansson     

/s/ James D. Robinson III

   Chairman of the Board and Director  
James D. Robinson III     

/s/ Vicki L. Sato, Ph.D.

   Director  
Vicki L. Sato, Ph.D.     

/s/ R. Sanders Williams, M.D.

   Director  
R. Sanders Williams, M.D.     
-----END PRIVACY-ENHANCED MESSAGE-----